Richard E. Champlin

TL;DR: Allogeneic hematopoietic stem cell transplantation (ASCT) is an effective consolidative strategy to decrease relapse for patients with acute myeloid leukemia (AML) and can cure ∼30% to 50% of patients with AML.

TL;DR: The combination of cyclophosphamide and etoposide provided an effective rescue treatment for many patients with advanced multiple myeloma resistant to conventional therapies and allowed early blood stem cell collection in support of subsequent myeloablative therapy for selected patients.

TL;DR: It is concluded that HDT–ASCT is well tolerated in patients with high-risk cardiac amyloidosis and can lead to improved overall outcomes.

TL;DR: The role of blinatumomab (Blin), a bi-specific T cell immunotherapy targeting CD19, as maintenance therapy following allogeneic HCT for adult patients with advanced B ALL is observed to be well tolerated, and strategies to increase CD8 levels and blockade against checkpoint inhibitors may overcome resistance to therapy.

TL;DR: The generation of AML-specific T-lymphocyte responses by leukemia-derived DC from CD14-selected monocytes isolated from healthy donor PBPC and loaded them with a total cell lysate from AML patient blasts support further research into the use of this strategy as an alternative approach to leukemia- derived DC vaccination.